^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Cholangiocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Pancreatic Cancer)
    New
    Title:

    Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

    Excerpt:
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

    Excerpt:
    ...somatic mutations in ATM, ATR, CHEK2, BRCA 1/2, RAD51, BRIP1, PALB2, PTEN, FANC, NBN, EMSY, MRE11, ARID1A] or germline mutations in the above genes....
    Trial ID:
    NCT04042831
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Transl Med
    Title:

    Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

    Excerpt:
    Samples from 122 individual patients with ICC were analyzed….BRCA1/2 mutations were detected in 16 (13%) patients...Four patients accepted poly ADP-ribose polymerase (PARP) inhibitor (olaparib) treatment combined with chemotherapy. Two patients achieved stable disease, and two patients responded partially.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://dx.doi.org/10.1186%2Fs12967-020-02437-2